Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. (February 2015)

• Record Type: Journal Article
• Authors: Simeone, Ester; Grimaldi, Antonio M; Ascierto, Paolo A
• Is Part Of: Melanoma management. Volume 2:Number 1(2015)
• Page Start: 41
• Page End: 50
• Publication Date: 2015-02
• Subjects: anti-PD-1 -- anti-PD-L1 -- immunotherapy -- metastatic melanoma -- MK3475 -- nivolumab; Melanoma -- Periodicals; 616.99477005
• DOI: 10.2217/mmt.14.30
• Languages: English
• ISSNs: 2045-0885

Abstract

SUMMARY : Programmed cell death receptor-1 (PD-1) and programmed cell death-1 ligand-1 (PD-L1) represent promising novel targets in immunotherapy. PD-1 is an inhibitory receptor involved in T-cell regulation that is expressed by activated T cells. Nivolumab and pembrolizumab are anti-PD-1 antibodies that have shown antitumor activity and acceptable tolerability in patients with metastatic melanoma in preclinical development and Phase I/II clinical trials. Several ongoing Phase III studies are further investigating the efficacy and safety of anti-PD-1 therapy in melanoma. Initial data on the combination of anti-PD-1 and anti-cytotoxic T-lymphocyte-associated antigen 4 blockade with nivolumab and ipilimumab also appear promising. Monoclonal antibodies to blockade PD-L1 may also be an effective immunotherapy strategy in melanoma and several anti-PD-L1 antibodies are in development.